Advertisement

Uroonkologie pp 783-841 | Cite as

Molekularbiologie und Genetik urogenitaler Tumoren

  • M.-O. Grimm
  • B. J. Schmitz-Dräger

Zusammenfassung

Die raschen Fortschritte in der Molekular- bzw. Zellbiologie haben unser Verständnis über Entstehung und Progression maligner Tumoren revolutioniert. Obwohl bereits 1914 der deutsche Zoologe Theodor Boveri chromosomale Veränderungen in Krebszellen beschrieben hatte, haben erst die in den letzten Jahren entwickelten Methoden der modernen Molekularbiologie die Entdeckung einiger der zugrundliegenden genetischen Alterationen möglich gemacht. In den folgenden Abschnitten werden diese für die häufigen urologischen Organtumoren zusammengefaßt. Dabei sollen nicht nur die pathogenetisch bedeutsamen Veränderungen an Chromosomen bzw. Genen beschrieben werden. Es soll darüber hinaus versucht werden aufzuzeigen, welche Ergebnisse der Grundlagenforschung künftig Einfluß auf Diagnostik und Therapie urogenitaler Tumoren haben könnten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Almon E, Goldfinger N, Kapon A, Schwartz D, Levine AJ, Rotter V (1993) Testicular tissue-specific expression of the p53 suppressor gene. Dev Biol 156:107–116PubMedGoogle Scholar
  2. Anglard P, Tory K, Brauch H et al. (1991) Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 51:1071–1077PubMedGoogle Scholar
  3. Anglard P, Tranhan E, Liu S et al. (1992) Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res 52:348–356PubMedGoogle Scholar
  4. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M (1992) Presence of ras oncogene mutations and human papilloma virus DNA in human prostate carcinoma. Cancer Res 52: 5991–5996PubMedGoogle Scholar
  5. Arason A, Barkardottir RB, Egilsson V (1993) Linkage analysis of chromosome-i7q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic-cancer. Am J Hum Genet 52:711–717PubMedGoogle Scholar
  6. Atkin NB, Baker MC (1985 a) Chromosome study of five cancers of the prostate. Hum Genet 70:359–364Google Scholar
  7. Atkin NB, Baker MC (1985 b) Chromosome 10 deletion in carcinoma of the prostate. New Engl J Med 312:315Google Scholar
  8. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R (1992) Growth regulation of human renal carcinoma cells: Role of transforming growth factor α. Cancer Res 52:3335–3339PubMedGoogle Scholar
  9. Barnes R, Masood S, Barker E et al. (1991) Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 139:245–250PubMedGoogle Scholar
  10. Bártek J, Bártková J, Vojtešek B et al. (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699–1703PubMedGoogle Scholar
  11. Bártková J, Bártek J, Lukaš J et al. (1991) P53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 49:196–202PubMedGoogle Scholar
  12. Berger MS, Greenfield C, Gullick WJ et al. (1987) Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 56:533–537PubMedGoogle Scholar
  13. Bergerheim U, Nordenskjöld M, Collins P (1989) Deletion mapping in human renal cell carcinoma. Cancer Res 49:1390–1396PubMedGoogle Scholar
  14. Bérubé NG, Speevak MD, Chevrette M (1994) Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosom del(12)(q 13). Cancer Res 54:3077–3081PubMedGoogle Scholar
  15. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS (1989) Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histo-pathological indicators of high metastatic potential. Cancer Res 49:5185–5190PubMedGoogle Scholar
  16. Bookstein R, Shew JY, Chen P-L, Scully P, Lee W-H (1990a) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715PubMedGoogle Scholar
  17. Bookstein R, Rio P, Madreperla S, Hong F, Allred C, Grizzle WE, Lee WH (1990 b) Promotor deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762–7766PubMedGoogle Scholar
  18. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369–3373PubMedGoogle Scholar
  19. Bosl GJ, Dmitrovsky E, Reuter VE et al. (1989) Isochromosome of chromosome 12: Clinically useful marker for male germ cell tumors. J Natl Cancer Inst 81:1874–1878PubMedGoogle Scholar
  20. Bosl GJ, Ilson DH, Rodriguez E, Motzer RJ, Reuter VE, Chaganti RSK (1994) Clinical relevance of the i (12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 86:349–355PubMedGoogle Scholar
  21. Bova GS, Carter BS, Bussemakers MJG et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869–3873PubMedGoogle Scholar
  22. Brachmann R, Lidquist PB, Nagashima M et al. (1989) Transmembrane TGF-α precursors activate EGF/TGF-α receptors. Cell 56:691–700PubMedGoogle Scholar
  23. Brewster SF, Browne S, and Brown KW (1994) Somatic allelic loss at the DCC, APC, nm23-H1 and P53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 151:1073–1077PubMedGoogle Scholar
  24. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HFM, Debruyne FMJ, Schalken JA (1993) Decreased E-Cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53:3241–3245PubMedGoogle Scholar
  25. Brooks JD, Bova GS, Isaacs WB (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26:35–39PubMedGoogle Scholar
  26. Bussemakers MJC, van Morselaar RJA, Giroldi L et al. (1992) Decreased expression of E-Cadherin in the progression of rat prostatic cancer. Cancer Res 52:2916–2922PubMedGoogle Scholar
  27. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA (1987) Enhanced expression of the c-myc protooncogene in high-grade prostate cancers. Prostate 11:327–337PubMedGoogle Scholar
  28. Cabrera G, Bass C, Elgavish A et al. (1995) Highly efficient gene transduction of bladder epithelium mediated by a recombinant adenoviral vector. Urol Res 23:277AGoogle Scholar
  29. Cairns P, Proctor AJ, Knowles MA (1991) Loss of heterozygosity at the Rb locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6:2305–2309PubMedGoogle Scholar
  30. Cairns P, Shaw ME, Knowles MA (1993) Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 53:1230–1232PubMedGoogle Scholar
  31. Cairns P, Mao L, Merlo et al. (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415–416PubMedGoogle Scholar
  32. Cama C, Olsson CA, Raffo AJ et al. (1995) Molecular staging of prostate cancer. IL A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 153: 1373–1378PubMedGoogle Scholar
  33. Carter BS, Ewing CM, Ward WS et al. (1990 a) Allelic loss of chromosomes 16 q and 10 q in human prostate cancer. Proc Natl Acad Sci USA 87:8751–8755PubMedGoogle Scholar
  34. Carter BS, Epstein JI, Isaacs WB (1990 b) Ras gene mutations in human prostate cancer. Cancer Res 50:6830–6832Google Scholar
  35. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH (1995) Mapping of regions of physical deletion on chromosome 16 q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 153:249–254PubMedGoogle Scholar
  36. Clairmont A, Ebert T, Weber H et al. (1994) Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase α messenger RNA in human renal cell carcinoma. CancerRes 54:1319–1323Google Scholar
  37. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301:592–595PubMedGoogle Scholar
  38. Connolly JM, Rose DP (1991) Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19:173–180PubMedGoogle Scholar
  39. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in mice with Interleukin 2 gene modified tumor cells. J Exp Med 177:1127–1134PubMedGoogle Scholar
  40. Cordon-Cardo C, Wartinger D, Petrylak D et al. (1992) Altered expression of the retinoblastoma gene product is a prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251–1256PubMedGoogle Scholar
  41. Cordon-Cardo C, Dalbagni G, Saez GT et al. (1994) p53 mutations in human bladder cancer: geno-typic versus phenotypic patterns. Int J Cancer 56:347–353PubMedGoogle Scholar
  42. Culig Z, Hobisch A, Cronauer MV et al. (1993) Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550PubMedGoogle Scholar
  43. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550–1552PubMedGoogle Scholar
  44. Davies P, Eaton CL, France TD, Phillips ME (1988) Growth factor receptors and oncogene expression in prostate cells. Am J Clin Oncol 11 [Suppl 2]:S1–7PubMedGoogle Scholar
  45. Davies P, Eaton CL (1989) Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate 14:123–132PubMedGoogle Scholar
  46. Deguchi T, Doi T, Ehara H et al. (1993) Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 53:5350–5354PubMedGoogle Scholar
  47. Dinjens WNM, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J (1994) Frequency and characterization of p 53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56:630–633PubMedGoogle Scholar
  48. Dong J-T, Lamb PW, Rinker-Schaeffer CW et al. (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome up 11.2. Science 268:884–886PubMedGoogle Scholar
  49. Dranoff G, Jaffee E, Lazenby A et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci 90:3539–3543PubMedGoogle Scholar
  50. Effert PJ, Neubauer A, Walther PJ, Liu ET (1992) Alterations of the p 53 gene are associated with the progression of a human prostate carcinoma. J Urol 147:789–793PubMedGoogle Scholar
  51. Effert PJ, McCoy RH, Walther PJ, Liu ET (1993) p53 gene alterations in human prostate carcinoma. J Urol 150:257–261Google Scholar
  52. Eickelmann P, Ebert T, Warskulat U, Schulz WA, Sies H (1994) Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases a and π in human renal cell carcinoma and in kidney cancer-derived cell lines. Carcinogenesis 15:219–225PubMedGoogle Scholar
  53. Emmert-Buck MR, Vocke CD, Pozzatti RO et al. (1995) Allelic loss on chromosome 8 p 12–21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959–2962PubMedGoogle Scholar
  54. Esrig D, Elmajian D, Groshen S et al. (1994) Accumulation of nuclear p 53 and tumor progression in bladder cancer. New Engl J Med 331:1259–1264PubMedGoogle Scholar
  55. Fan K (1988) Heterogenous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of p21 protein as a predictor for bone metastasis. J Urol 139:318PubMedGoogle Scholar
  56. Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B (1985) Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318:377–380PubMedGoogle Scholar
  57. Fishel R, Lescoe MK, Rao MRS et al. (1993) The human mutator gene homolog MSH 2 and ist association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038PubMedGoogle Scholar
  58. Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP (1994) Mutations of the p 53 gene are not detectable in human testicular tumors. Mod Pathol 7:435–439PubMedGoogle Scholar
  59. Fleming WH, Hamel A, MacDonald R et al. (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:1535–1538PubMedGoogle Scholar
  60. Fowler JE Jr, Lau JLT, Ghosh L, Mills SE, Mounzer A (1988) Epidermal growth factor and prostatic carcinoma: an immunhistochemical study. J Urol 139:857–861PubMedGoogle Scholar
  61. Fox SB, Persad RA, Royds J, Kore RN, Silcocks PB, Collins CC (1993) P53 and c-myc expression in stage Ai prostatic adenocarcinoma: useful prognostic determinants? J Urol 150:490–494PubMedGoogle Scholar
  62. Freeman MR, Washecka R, Chung LWK (1989) Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res 49:6221–6225PubMedGoogle Scholar
  63. Frixen UH, Behrens J, Sachs M et al. (1991) E-Cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113:173–185PubMedGoogle Scholar
  64. Fujimoto K, Yamada Y, Okajima E et al. (1992) Frequent association of p53 gene mutations in invasive bladder cancer. Cancer Res 52:1393–1398PubMedGoogle Scholar
  65. Fujita J, Srivastava SK, Kraus MH (1985) Frequency of molecular alterations affecting ras protoon-cogenes in human urinary tract tumors. Proc Natl Acad Sci 82:3849–3853PubMedGoogle Scholar
  66. Fung Y-KT, T’Ang A, Murphree AL et al. (1993) The Rb gene suppresses the growth of normal cells. Oncogene 8:2659–2672PubMedGoogle Scholar
  67. Gaddipati JP, McLeod DG, Heidenberg HB et al. (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864PubMedGoogle Scholar
  68. Ganguly S, Murty VV, Samaniego F, Reuter VE, Bosl GJ, Chaganti RS (1990) Detection of preferential NRAS mutations in human male germ cell tumors by polymerase chain reaction. Genes Chromosomes Cancer 1:228–232PubMedGoogle Scholar
  69. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ (1993) Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 53:2723–2727PubMedGoogle Scholar
  70. Gao X, Zacharek A, Salkowski A et al. (1995) Loss of heterozygosity of the BRCA1 and other loci on chromosome 17 q in human prostate cancer. Cancer Res 55:1002–1005PubMedGoogle Scholar
  71. Gastl G, Finstad CL, Guarini A et al. (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52:6229–6236PubMedGoogle Scholar
  72. Gibas Z, Prout GR Jr, Connolly JG, Pontes JE, Sandberg AA (1984) Nonrandom chromosomal changer in transitional cell carcinoma of the bladder. Cancer Res 44:1257–1264PubMedGoogle Scholar
  73. Gibas Z, Pontes JE, Sandberg AA (1985) Chromosome rearrangements in a metastatic adenocarcinoma of the prostate. Cancer Genet Cytogenet 16:301–304PubMedGoogle Scholar
  74. Gibas Z, Prout GR, Pontes JE, Connolly JG, Sandberg AA (1986) A possible specific chromosome change in transitional cell carcinoma of the bladder. Cancer Genet Cytogenet 19:229–238PubMedGoogle Scholar
  75. Gnarra JR, Tory K, Weng Y et al. (1994) Mutations of the VHL tumour suppressor gene in renal cell carcinoma. Nature Gen 7:85–90Google Scholar
  76. Golumbek PT, Lazenby AJ, Levitsky HI et al. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713–716PubMedGoogle Scholar
  77. Gonzalez-Zulueta M, Ruppert JM, Tokino K et al. (1993) Microsatellite instability in bladder cancer. Cancer Res 53:5620–5623PubMedGoogle Scholar
  78. Goodrich DW, Chen Y, Scully P, Lee H-W (1992) Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation. Cancer Res 52:1968–1973PubMedGoogle Scholar
  79. Gore ME, Collins MK (1994) Gene therapy for cancer. Eur J Cancer 30A: 1047–1049PubMedGoogle Scholar
  80. Goustin AS, Leof EB, Shipley GD, Moses HL (1986) Growth factors and cancer. Cancer Res 46:1015–1029PubMedGoogle Scholar
  81. Grimm M-O, Jürgens B, Schulz WA, Decken K, Makri D, Schmitz-Dräger BJ (1995) Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res 23:293–300PubMedGoogle Scholar
  82. Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW (1991) Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51:1632–1637PubMedGoogle Scholar
  83. Habuchi T, Ogawa O, Kakehi Y et al. (1992) Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol 148:1595–1599PubMedGoogle Scholar
  84. Habuchi T, Ogawa O, Kakehi et al. (1993 a) Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 53:579–584Google Scholar
  85. Habuchi T, Takahashi R, Yamada H et al. (1993 b) Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087–1088Google Scholar
  86. Haugen A, Ryberg D, Hansteen I-L, Amstad P (1990) Neoplastic transformation of a human kidney epithelial cell line transfected with v-Ha-ras oncogene. Int J Cancer 45:572–577PubMedGoogle Scholar
  87. Haut M, Steeg PS, Willson JKV, Markowitz SD (1991) Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential. J Natl Cancer Inst 83:712–716PubMedGoogle Scholar
  88. Horowitz JM, Yandell DW, Park S-H et al. (1989) Point mutational inactivation of the retinoblastoma antioncogene. Science 243:937–940PubMedGoogle Scholar
  89. Horowitz JM, Park S-H, Bogenmann E et al. (1990) Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci 87:2775–2779PubMedGoogle Scholar
  90. Hosoe S, Brauch H, Latif F et al. (1990) Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8:634–640PubMedGoogle Scholar
  91. Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p 53 alleles. Cancer Res 51:4716–4720PubMedGoogle Scholar
  92. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing CM (1994) Molecular biology of prostate Cancer. Sem Oncol 21:514–521Google Scholar
  93. Ishikawa J, Xu H-J, Hu S-X et al. (1991) Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51:5736–5743PubMedGoogle Scholar
  94. Ichikawa T, Ichikawa Y, Dong J et al. (1992) Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52:3486–3490PubMedGoogle Scholar
  95. Israeli RS, Miller WH, Su SL et al. (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54:6306–6310PubMedGoogle Scholar
  96. Israeli RS, Miller WH Jr, Su SL et al. (1995) Sensitive detection of prostatic hematogenous tumor cell dissemination using prostatic specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153:573–577PubMedGoogle Scholar
  97. Kai M, Arakawa H, Sugimoto Y, Murata Y, Ogawa M, Nakamura Y (1995) Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res 86:249–251PubMedGoogle Scholar
  98. Kamb A, Gruis NA, Weaver Feldhaus J et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440PubMedGoogle Scholar
  99. Katz AE, Olsson CA, Raffo AJ et al. (1994) Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43:765–775PubMedGoogle Scholar
  100. Keen AJ, Knowles MA (1994) Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083–2088PubMedGoogle Scholar
  101. Kellens RE (1993) Gene amplification in mammalian cells. A comprehensive guide. Marcel Dekker, New YorkGoogle Scholar
  102. Kessel AG van, Suijkerbuijk RF, Sinke RJ, Looijenga L, Oosterhuis JW, de Jong B (1993) Molecular cytogenetics of human germ cell tumours: i(i2p) and related chromosomal anomalies. Eur Urol 23:23–29Google Scholar
  103. Klocker H, Culig Z, Hobisch A, Cato ACB, Bartsch G (1994) Androgen receptor alterations in prostatic carcinoma. Prostate 25:266–273PubMedGoogle Scholar
  104. Knowles MA, Williamson M (1993) Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 53:133–139PubMedGoogle Scholar
  105. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM (1992) K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69:2293–2299PubMedGoogle Scholar
  106. Kovacs G (1993) Molekularzytogenetische Aspekte der Entstehung und Progredienz von Nieren-zellkarzinomen. Immuntherapie in der Uroonkologie. Springer, Berlin Heidelberg New York Tokyo, S 145–150Google Scholar
  107. Kovacs G, Erlandsson R, Boldog F et al. (1988) Consistent chromosome 3 p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci 85:1571–1575PubMedGoogle Scholar
  108. Kovacs G, Kung HF (1991) Nonhomologous chromatid exchange in hereditary and sporadic renal cell carcinomas. Proc Natl Acad Sci 88:194–198PubMedGoogle Scholar
  109. Kuczyk MA, Serth J, Bokemeyer C et al. (1994) Overexpression of the p 53 oncoprotein in carcinoma in situ of the testis. Pathol Res Pract 190:993–998PubMedGoogle Scholar
  110. Kuczyk MA, Serth J, Bokemeyer C, Jonas U (1995) Expression von c-kit und Stem Cell Factor (SCF) an Hodentumoren und Hodentumorzellinien. Urologe A [Supppl 1]: S118 (astract)Google Scholar
  111. Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP (1991) Allelotyping of human prostatic adenocarcinoma. Genomics 11:530–536PubMedGoogle Scholar
  112. Lacombe ML, Sastre-Garau X, Lascu et al. (1991) Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours. Eur J Cancer 27:1302–1307PubMedGoogle Scholar
  113. Latif F, Tory K, Gnarra J et al. (1993) Identification of the von Hippel-Lindau tumor suppressor gene. Science 260:1317–1320PubMedGoogle Scholar
  114. Latil A, Baron JC, Cussenot O et al. (1994) Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 59:637–638PubMedGoogle Scholar
  115. Leach NS, Nicolaides NC, Papadopoulos N et al. (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225PubMedGoogle Scholar
  116. Li FP, Decker HJH, Zbar B et al. (1993) Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3; 8 translocation. Ann Intern Med 118:106–111PubMedGoogle Scholar
  117. Linnenbach AJ, Robbins SL, Seng BA, Tomaszewski JE, Pressler LB, Malkowicz SB (1994) Urothelial carcinogenesis. Science 367:419–420Google Scholar
  118. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional-call bladder cancer and its prognostic value. Int J Cancer 53:365–370PubMedGoogle Scholar
  119. Logothetis CJ, Xu H-J, Ro JY, Hu S-X, Sahin A, Ordonez N, Benedict WF (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84:1256–1261PubMedGoogle Scholar
  120. Lundgren R Kristoffersson U, Heim S, Mandahl N, Mitelman F (1988) Multiple structural chromosome rearrangements, including del(7q) and del (10 q), in an adenocarcinoma of the prostate. Cancer Genet Cytogenet 35:103–108PubMedGoogle Scholar
  121. Lynch HT, Smyrk TC, Watson P et al. (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104: 1535–1549PubMedGoogle Scholar
  122. MacGrogan D, Levy A, Bostwick DG, Wagner M, Wells D, Bookstein R (1994) Loss of chromosome arm 8 p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromsom Cancer 10:151–159Google Scholar
  123. Maddy SQ, Chisholm GD, Busuttil A, Habib FK (1989) Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumor. Br J Cancer 60: 41–44PubMedGoogle Scholar
  124. Makri D, Schulz WA, Grimm M-O, Schmitz-Dräger BJ (1995) Rapid killing of urothelial carcinoma cells by wild-type p53. Int J Oncol 7:637–641PubMedGoogle Scholar
  125. Marshall RS, Paterson MC, Rauth AM (1991) DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer prone family. Carcinogenesis 12:1175–1180PubMedGoogle Scholar
  126. Marx J (1994) New tumor suppressor may rival p53. Science 264:344–345PubMedGoogle Scholar
  127. McCann A, Dervan PA, Guillick WJ, Carney DN (1989) c-erbB-2 oncoprotein expression in malignant and non-malignant tissues (abstract). Proc Am Assoc Cancer Res 30:914Google Scholar
  128. Massenkeil G, Oberhuber H, Hailemariam S et al. (1994) p53 mutations and loss of heterozygosity on chromosomes 8p, 16 q, 17 p, and 18 q are confined to advanced prostate cancer. Anticancer Res 14:2785–2790PubMedGoogle Scholar
  129. Messing EM (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50:2530–2537PubMedGoogle Scholar
  130. Mickisch GH, Schroeder FH (1994) From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists. World J Urol 12:104–111PubMedGoogle Scholar
  131. Miyao N, Tsai YC, Lerner SP et al. (1993) Role of chromosome 9 in bladder cancer. Cancer Res 53:4066–4070PubMedGoogle Scholar
  132. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB (1994) Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 24:244–251PubMedGoogle Scholar
  133. Moolenar WH, Rob JA, Tertoolen LGJ, de Laat SW (1986) The epidermal growth factor induced signal in A 431 cells. J Biol Chem 261:279–284Google Scholar
  134. Moreno JG, Croce CM, Fischer R et al. (1992) Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110–6112PubMedGoogle Scholar
  135. Moriyama M, Akiyama T, Yamamoto T et al. (1991) Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol 145:423–427PubMedGoogle Scholar
  136. Morris GL, Dodd JG (1990) Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143:1272–1274PubMedGoogle Scholar
  137. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB (1993) Reduction of E-Cadherin levels and deletion of the a-Catenin gene in human prostate cancer cells. Cancer Res 53:3585–3590PubMedGoogle Scholar
  138. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH (1992 a) Infrequent ras oncogene mutations in human prostate cancer. Prostate 20:327–338Google Scholar
  139. Moul JW, Theune SM, Chang EH (1992b) Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosom Cancer 5:109–118PubMedGoogle Scholar
  140. Mulder MP, Keijzer W, Verkerk A et al. (1989) Activated ras genes in human seminoma: evidence for tumor heterogeneity. Oncogene 4:1345–1351PubMedGoogle Scholar
  141. Murty VVVS, Houldsworth J, Baldwin S et al. (1992) Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. Proc Natl Acad Sci 89:11006–11010PubMedGoogle Scholar
  142. Murty VVVS, Bosl GJ, Houldsworth J et al. (1994 a) Allelic loss and somatic differentiation in human male germ cell tumors. Oncogene 9:2245–2251PubMedGoogle Scholar
  143. Murty VVVS, Li R-G, Houldsworth J et al. (1994 b) Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. Oncogene 9:3227–3231PubMedGoogle Scholar
  144. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston D, Fair W (1989) Expression of transforming growth factor a and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney. Cancer Res 49:3407–3411PubMedGoogle Scholar
  145. Myers RB, Oelschlager D, Srivastava S, Grizzle WE (1994) Accumulation of the p 53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25:243–248PubMedGoogle Scholar
  146. Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP (1990) Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 143:175–178PubMedGoogle Scholar
  147. Navone NM, Troncoso P, Pisters LL et al. (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657–1669PubMedGoogle Scholar
  148. Neal DE, Marsh C, Bennett MK et al. (1985) Epidermal growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1:366–368Google Scholar
  149. Neal DE, Sharpies L, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619–1625PubMedGoogle Scholar
  150. Newmark JR, Hardy DO, Tonb DC et al. (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89:6319–6323PubMedGoogle Scholar
  151. O’Brien SG, Kirkland MA, Goldman JM (1994) Antisense therapy for malignant disease. Eur J Cancer 30A: 1160–1164PubMedGoogle Scholar
  152. Olumi AF, Tsai YC, Nichols PW et al. (1990) Allelic loss of chromosome 17 p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7081–7083PubMedGoogle Scholar
  153. Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübben H, Raz A (1994) Inverse relation of E-Cadherin and Autocrine Motility Factor Receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:3120–3123PubMedGoogle Scholar
  154. Pathak S, Strong LC, Ferell RE, Trindade A (1982) Familial renal cell carcinoma with a 3; 11 chromosome translocation limited to tumor cells. Science 217:939–941PubMedGoogle Scholar
  155. Peltomäki P, Alfthan O, de la Chapelle A (1991 a) Oncogenes in human testicular cancer: DNA and RNA studies. Br J Cancer 63:851–858PubMedGoogle Scholar
  156. Peltomäki P, Lothe R, B0rresen A-L, Fossa SD, Brogger A, de la Chapelle A (1991b) Altered dosage of the sex chromosomes in human testicular cancer: a molecular genetic study. Int J Cancer 47:518–522PubMedGoogle Scholar
  157. Peng H-Q, Hogg D, Malkin D et al. (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53:3574–3578PubMedGoogle Scholar
  158. Peng H-Q, Bailey D, Bronson D, Goss PE, Hogg D (1995) Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res 55:2871–2875PubMedGoogle Scholar
  159. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G (1990) Modulation of pro-epidermal growth factor, pre-transforming growth factor α and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 50:3934–3939PubMedGoogle Scholar
  160. Phillips ME, Ferro MA, Smith PJ, Davies P (1987) Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. Urol Int 42:115–119PubMedGoogle Scholar
  161. Phillips SMA, Morton DG, Lee SJ, Wallace DMA, Neoptelemos JP (1994) Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosome 10 p, 10 q, and 16 q in human prostate cancer. Br J Urol 73:390–395PubMedGoogle Scholar
  162. Presti JC, Reuter VE, Galan T, Fair WR, Cordon-Cardo C (1991) Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51:5405–5409PubMedGoogle Scholar
  163. Presti JC, Reuter VE, Cordon-Cardo C, Mazumdar M, Fair WR, Jhanwar SC (1993) Allelic deletions in renal tumors: Histopathological correlations. Cancer Res 53:5780–5783PubMedGoogle Scholar
  164. Quarmby VE, Yarbrough WG, Lubahn DB, French FS, Wilson EM (1990) Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4:22–28PubMedGoogle Scholar
  165. Rao JY, Hemstreet III GP, Hurst RE et al. (1993) Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci 90:8287–8291PubMedGoogle Scholar
  166. Reddy EP, Reynolds RK, Santos E, Barbacid M (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 bladder carcinoma oncogene. Nature 300: 149–152PubMedGoogle Scholar
  167. Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM (1993) Chromosome 17 p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53:3092–3097PubMedGoogle Scholar
  168. Reznikoff CA, Kao C, Messing EM, Newton M, Swaminathan S (1993) A molecular genetic model of human bladder carcinogenesis. Cancer Biol 4:143–152Google Scholar
  169. Rijnders AW, van der Korput JA, van Steenbrugge GJ, Romijn JC, Trapman J (1985) Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Comm 132: 548–554PubMedGoogle Scholar
  170. Rodriguez E, Mathew S, Reuter V, Ilson DH, Bosl GJ, Chaganti RSK (1992) Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52:2285–2291PubMedGoogle Scholar
  171. Rosenberg SA (1994) The gene therapy of cancer. Prev Med 23:624–626PubMedGoogle Scholar
  172. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1993) Identification of an NAD(P)H:quino-ne oxidoreductase polymorphism and its association with lung cancer. Proc Am Ass Cancer Res 34:144Google Scholar
  173. Ruppert JM, Tokino K, Sidransky D (1993) Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53:5093–5095PubMedGoogle Scholar
  174. Russel SJ (1994) Replicating Vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer 30A: 1165–1171Google Scholar
  175. Sadi MV, Barrack ER (1993) Image analysis of androgen receptor immunostaining in metastatic prostate cancer — heterogeneity as a predictor of response to hormonal therapy. Cancer 71:2574–2580PubMedGoogle Scholar
  176. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a guide to methods and applications. Cold Spring Harbour, New YorkGoogle Scholar
  177. Sanchez Y, El-Naggar A, Pathak S, McNeill Killary A (1994) A tumor suppressor locus within 3 p 14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci 91:3383–3387PubMedGoogle Scholar
  178. Sanda MG, Ayyagari SR, Jaffee EM et al. (1994) Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622–628PubMedGoogle Scholar
  179. Sandberg AA (1992) Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 23:368–380PubMedGoogle Scholar
  180. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85:53–59PubMedGoogle Scholar
  181. Sato K, Moriyama M, Mori S et al. (1992) An immunhistologic evaluation of c-erbB-2 gene product in patients with bladder carcinoma. Cancer 70:2493–2498PubMedGoogle Scholar
  182. Schenkman NS, Sesterhenn IA, Washington L et al. (1995) Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. J Urol 154:617–621PubMedGoogle Scholar
  183. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566–1572PubMedGoogle Scholar
  184. Schmidt B, Ackermann R, Strohmeyer T (1995) Molecular biology of testicular germ cell tumors: current status. J Mol Med 73:355–367PubMedGoogle Scholar
  185. Schmitz-Dräger BJ, van Roeyen CRC, Grimm M-O et al. (1994) p53 accumulation in precursor lesions lesions and early stages of bladder cancer. World J Urol 12:79–83PubMedGoogle Scholar
  186. Schmitz-Dräger BJ, van Roeyen CRC, Gerharz C-D et al. (1995) p53 and c-myc during development and progression of bladder cancer. Eur Urol (eingereicht)Google Scholar
  187. Seizinger BR, Rouleau GA, Ozelius LJ et al. (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268–269PubMedGoogle Scholar
  188. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) p53 immuno-histochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71:201–205PubMedGoogle Scholar
  189. Shuin T, Kondo K, Torigoe S et al. (1994 a) Frequent somatic mutations and loss of heterozygosity of the Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852–2855PubMedGoogle Scholar
  190. Shuin T, Misaki H, Kubota Y, Yao M, Hosaka M (1994b) Differential expression of protooncogenes in human germ cell tumors of the testis. Cancer 73:1721–1727PubMedGoogle Scholar
  191. Shimizu M, Yokota J, Mori N et al. (1990) Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. Oncogene 5:185 – 194PubMedGoogle Scholar
  192. Shipman R, Schraml P, Colombi M, Raefle G, Ludwig CU (1993) Loss of heterozygosity on chromosome 11p 13 in primary bladder carcinoma. Hum Genet 91:455–458PubMedGoogle Scholar
  193. Sidransky D, von Eschenbach A, Tsai YC et al. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706–709PubMedGoogle Scholar
  194. Sidransky D, Frost P, von Eschenbach A et al. (1992) Clonal origin of bladder cancer. New Engl J Med 326:737–740PubMedGoogle Scholar
  195. Siegel D, Beall H, Senekowitsch C et al. (1992) Bioreductive activation of mitomycin C by DT-dia-phorase. Biochem 31:7879–7885Google Scholar
  196. Sikora K, Evan G, Stewart J, Watson JV (1985) Detection of the c-myc oncogene product in testicular cancer. Br J Cancer 52:171–176PubMedGoogle Scholar
  197. Sitaras NM, Sariban E, Bravo M, Pantazis P, Antoniades HN (1988) Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 48:1930–1935PubMedGoogle Scholar
  198. Smeets W, Pauwels R, Laarakkers L, Debruyne F, Geraedts J (1987) Chromosomal analysis of bladder cancer. III. Nonrandom alterations. Cancer Genet Cytogenet 29:29–41PubMedGoogle Scholar
  199. Solomon E, Voss R, Hall V, Rider SH (1987) Chromosome 5 allele loss in human colorectal carcinomas. Nature 328:616–619PubMedGoogle Scholar
  200. Spruck III CH, Gonzalez-Zulueta M, Shibata A et al. (1994 a) p16 gene in uncultured tumours. Nature 370:183–184PubMedGoogle Scholar
  201. Spruck III CH, Ohneseit PF, Gonzalez-Zulueta M et al. (1994 b) Two molecular pathways in transitional cell carcinoma of the bladder. Cancer Res 54:784–788PubMedGoogle Scholar
  202. Stacey SN, Nielsen I, Skouv J, Hansen C, Autrup H (1990) Deregulation in trans of c-myc expression in immortalized human urothelial cells and in T24 bladder carcinoma cells. Mol Carcinogen 3:216–225Google Scholar
  203. Stadler WM, Sherman J, Bohlander SK et al. (1994) Homozygous deletions within chromosomal bands 9 p 21–22 in bladder cancer. Cancer Res 54:2060–2063PubMedGoogle Scholar
  204. Strohmeyer T, Peter S, Hartmann M et al. (1991 a) Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51:1811–1816PubMedGoogle Scholar
  205. Strohmeyer T, Reissmann P, Cordon-Cardo C et al. (1991b) Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci 88: 6662–6666PubMedGoogle Scholar
  206. Strohmeyer T, Reese D, Press M et al. (1995) Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 153:511–515PubMedGoogle Scholar
  207. Suijkerbuijk RF, Sinke RJ, Olde Weghuis DEM et al. (1994) Amplification of chromosome subre-gion 12 p 11.2-p 12.1 in a metastasis of an I(12p)-negative seminoma: relationship to tumor progression. Cancer Genet Cytogenet 78:145–152PubMedGoogle Scholar
  208. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Molec Biol 46:759–765PubMedGoogle Scholar
  209. Suzuki Y, Tamura G, Satodate R, Fujioka T (1992) Infrequent mutation of p 53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 83:233–235PubMedGoogle Scholar
  210. Tabin CJ, Bradley SM, Bargmann C et al. (1982) Mechamism of activation of a human oncogene. Nature 300:143–149PubMedGoogle Scholar
  211. Takahashi R, Hashimoto T, Xu H-J et al. (1991) The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci 88:5257–5261PubMedGoogle Scholar
  212. Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenic regulator. Science 251: 1451–1455PubMedGoogle Scholar
  213. Thoenes W, Störkel S, Rumpelt HJ (1986) Histopathology of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181:125–143PubMedGoogle Scholar
  214. Tory K, Brauch H, Linehan M et al. (1989) Specific genetic changes in tumors associated with von Hippel Lindau disease. J Natl Cancer Inst 81:1097–1101PubMedGoogle Scholar
  215. Trapman J, Sleddens HF, van der Weiden MM et al. (1994) Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54:6061–6064PubMedGoogle Scholar
  216. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA (1990) Allelic loss of chromosome 9, 11, and 17 in human bladder cancer. Cancer Res 50:44–47PubMedGoogle Scholar
  217. Tsuura Y, Hiraki H, Watanabe K et al. (1994) Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dys-germinoma in human immunhistochemical study on formalin fixed, paraffin-embedded tissues. Virchows Archiv 424:135–141PubMedGoogle Scholar
  218. Uchida T, Wada C, Wang, C, Egawa S, Ohtani H, Koshiba K (1994) Genomic instability of micro-satellite repeats and mutations of H-, K-, and N-ras, and p 53 genes in renal cell carcinoma. Cancer Res 54:3682–3685PubMedGoogle Scholar
  219. Umbas R, Schalken JA, Aalders TW et al. (1992) Expression of the cellular adhesion molecule E-Cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104–5109PubMedGoogle Scholar
  220. Umbas R, Isaacs WB, Bringuier PB et al. (1994) Decreased E-Cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929–3933PubMedGoogle Scholar
  221. Vanni R, Scarpa RM (1986) Correspondence. Cancer Res 46:4873Google Scholar
  222. Varma VA, Austin GE, O’Connell AC (1989) Antibodies to ras oncogene p21 lack immunohistochemical specificity for neoplastic epithelium in human prostatic tissue. Arch Pathol Lab Med 113:16–19PubMedGoogle Scholar
  223. Veldhuizen PI van, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL (1993) Mutant p53 expression in prostate carcinoma. Prostate 22:23–30PubMedGoogle Scholar
  224. Veldscholte J, Ris-Stalpers C, Kuiper GGJM et al. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding chracteristics and response to anti-androgens. Biochem Biophys Res Comm 17:534–540Google Scholar
  225. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (1992) Antiandrogens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat shock protein interaction, and transcription activation. Biochemistry 31:2393–2399PubMedGoogle Scholar
  226. Vieweg J, Rosenthal FM, Bannerji R et al. (1994) Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765PubMedGoogle Scholar
  227. Viola MV, Fromowitz F, Oravez S et al. (1986) Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314:133–137PubMedGoogle Scholar
  228. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883–887PubMedGoogle Scholar
  229. Visakorpi T, Hyytinen E, Koivisto P et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Gen 9:401–406Google Scholar
  230. Vleminckx K, Vakaet JL, Mareel M, Fiers W, Van Roy F (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107–119PubMedGoogle Scholar
  231. Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal tumor development. N Engl J Med 319:525–532PubMedGoogle Scholar
  232. Wang L, Vass W, Gao C, Chang KSS (1987) Amplification and enhanced expression of the c-Ki-ras2 protooncogene in human embryonal carcinomas. Cancer Res 47:4192–4198PubMedGoogle Scholar
  233. Wang N, Perkins KL (1984) Involvement of band 3p 14 in t (3; 8) hereditary renal cell carcinoma. Cancer Genet Cytogenet 11:479–481PubMedGoogle Scholar
  234. Watson JV, Stewart J, Evan GI, Ritson A, Sikora K (1986) The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 53:331–337PubMedGoogle Scholar
  235. Weidner U, Peter S, Strohmeyer T, Hussnätter R, Ackermann R, Sies H (1990) Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 50:4504–4509PubMedGoogle Scholar
  236. Werthman P, Drazan KE, Csete ME et al. (1994) Adenoviral-mediated transfer of human p 53 tumor suppressor gene to rat bladder in vivo. J Urol 151:389AGoogle Scholar
  237. Whartenby KA, Abboud CN, Marrogi AJ, Ramesh R, Freeman SM (1995) The biology of cancer gene therapy. Lab Invest 72:131–145PubMedGoogle Scholar
  238. Wilding G, Chen M, Gelmann EP (1989) Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103–115PubMedGoogle Scholar
  239. Wood DP, Fair WR, Chaganti RSK (1992) Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. J Urol 147:274–277PubMedGoogle Scholar
  240. Wright C, Mellon K, Neal DE, Johnson P, Corbett I, Home CHW (1990) Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer 62:764–765PubMedGoogle Scholar
  241. Wright C, Mellon K, Johnston P et al. (1991) Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63:967–970PubMedGoogle Scholar
  242. Xu H-J, Cairns P, Hu S-X, Knowles MA, Benedict WF (1993) Loss of Rb expression in primary bladder cancer correlates with loss of heterozygosity at the Rb locus and tumor progression. Int J Cancer 53:781–784PubMedGoogle Scholar
  243. Yamamoto T, Ikawa S, Akiyama T et al. (1986) Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319:230–234PubMedGoogle Scholar
  244. Yoshida MA, Ohyashiki K, Ochi H et al. (1986) Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res 46:2139–2147PubMedGoogle Scholar
  245. Zbar B, Tory K, Merino M et al. (1994) Hereditary papillary renal cell carcinoma. J Urol 151:561–566PubMedGoogle Scholar
  246. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ (1994 a) Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7 q 31.1. Cancer ResGoogle Scholar
  247. 54:6370–6373Google Scholar
  248. Zenklusen JC, Bieche I, Lidereau R, Conti CJ (1994 b) CA microsatellite repeat D7S522 is the most commonly deleted region in human breast cancer. Proc Natl Acad Sci 91:12155–12158Google Scholar
  249. Zenklusen JC, Barrett JC, Oshimura M, Conti CJ (1994 c) Inhibition of tumorigenicity of a murine squamous cell carcinoma (SCC) cell line by a putative tumor suppressor gene on human chromosome 7. Oncogene 9:2817–2825Google Scholar
  250. Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, Hung M-C (1990) Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinogen 3:254–257Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • M.-O. Grimm
  • B. J. Schmitz-Dräger

There are no affiliations available

Personalised recommendations